Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports events occurring on January 17, 2025. The filing details a significant debt-for-equity exchange and the company's ongoing efforts to regain compliance with Nasdaq continued listing standards following a prior delisting notice.
Key Financial Metrics and Transaction Details
- Debt Exchange: The company exchanged $22,347,543 in principal amount of outstanding Senior Secured Convertible Notes (plus accrued interest) for 22,347 shares of Series C Convertible Preferred Stock.
- Remaining Debt: The outstanding principal balance of the remaining Convertible Notes is approximately $6.6 million.
- Equity Impact: The exchange was executed to increase stockholders' equity to meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders' equity. The filing states equity is now "significantly in excess" of this threshold.
- Conversion Potential:
- At the voluntary conversion price of $1.068 per share, the Series C Preferred Stock could convert into approximately 20,924,157 shares of common stock.
- At the floor price of $0.2136 per share, the Series C Preferred Stock could convert into approximately 104,620,787 shares of common stock.
Material Changes and Listing Status
The primary material change is the reduction of debt and the issuance of preferred stock to address a Nasdaq delisting risk. The company previously failed to meet the $35 million market value of listed securities requirement (Rule 5550(b)(2)) as of March 2024. After a hearing on October 29, 2024, the Nasdaq Hearings Panel granted an extension until January 31, 2025, to regain compliance. The current exchange targets compliance under the alternative stockholders' equity standard.
Outlook, Risks, and Management Commentary
- Delisting Risk: While the exchange significantly boosts stockholders' equity, the filing explicitly states there is no assurance that the Nasdaq Hearings Panel will determine the company has regained compliance with continued listing standards.
- Dilution Risk: The potential issuance of up to ~104.6 million shares upon conversion at the floor price represents a significant potential dilution to existing common stockholders.
- Regulatory Exemption: The sale of Series C Preferred Stock and underlying common stock is exempt from registration under Section 3(a)(9) of the Securities Act as an exchange with existing security holders.
Investor Verification Checklist
- Verify the final determination by the Nasdaq Hearings Panel regarding the company's compliance status by the January 31, 2025 deadline.
- Review the full terms of the Series C Convertible Preferred Stock (Certificate of Designations) to understand liquidation preferences and voting rights.
- Monitor the remaining $6.6 million Convertible Note balance and its maturity terms.
- Assess the potential dilution impact based on the current market price relative to the $1.068 voluntary conversion price and the $0.2136 floor price.